Strides Pharma Science Limited (BOM:532531)
India · Delayed Price · Currency is INR 865.60
-12.00 (-1.37%)
At close: Feb 12, 2026
Strides Pharma Science Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Net Income | 35,935 | -706.12 | -2,026 | -4,602 | 2,684 |
Depreciation & Amortization | 1,854 | 2,123 | 2,301 | 2,162 | 1,888 |
Other Amortization | 68.6 | 83.99 | 131.21 | 168.49 | 174.59 |
Loss (Gain) From Sale of Assets | -40.95 | -14.32 | -41.07 | 41.9 | -23.38 |
Asset Writedown & Restructuring Costs | 0.05 | 1,575 | 330.4 | 1,774 | - |
Loss (Gain) From Sale of Investments | -1,021 | - | -656.07 | -558.62 | -241.01 |
Loss (Gain) on Equity Investments | -18.37 | 1,757 | 2,853 | 1,108 | 978.19 |
Stock-Based Compensation | 16.09 | 15.86 | 13.01 | -7.09 | 68.02 |
Provision & Write-off of Bad Debts | 10.85 | 175.67 | 344.17 | 1.78 | 94.61 |
Other Operating Activities | -28,323 | 2,809 | 1,773 | -767.15 | 2,471 |
Change in Accounts Receivable | -516.33 | 390.9 | -3,474 | -587.95 | -1,248 |
Change in Inventory | -2,170 | 307.04 | -81.38 | 281.86 | -4,140 |
Change in Accounts Payable | 1,049 | -1,485 | -1,023 | -1,593 | 2,108 |
Operating Cash Flow | 6,844 | 7,011 | 444.11 | -2,578 | 4,814 |
Operating Cash Flow Growth | -2.38% | 1478.58% | - | - | 135.09% |
Capital Expenditures | -2,425 | -1,182 | -949.38 | -1,434 | -2,975 |
Sale of Property, Plant & Equipment | 681.03 | 888.06 | 72.58 | 753.74 | 39.58 |
Cash Acquisitions | -78.77 | -58.78 | - | -2,195 | -78.86 |
Divestitures | - | 66.69 | 5,193 | - | - |
Investment in Securities | 331.75 | -765.96 | -1,561 | 1,569 | -2,449 |
Other Investing Activities | 154.44 | 90.69 | 269.64 | 118.67 | 254.63 |
Investing Cash Flow | -896.89 | -1,503 | 3,025 | -1,187 | -5,208 |
Short-Term Debt Issued | - | 2,424 | - | 4,564 | - |
Long-Term Debt Issued | 1,714 | 1,073 | 3,304 | 4,507 | 5,675 |
Total Debt Issued | 1,714 | 3,498 | 3,304 | 9,071 | 5,675 |
Short-Term Debt Repaid | -2,030 | - | -504.55 | - | -1,824 |
Long-Term Debt Repaid | -3,535 | -7,901 | -3,081 | -3,132 | -2,472 |
Total Debt Repaid | -5,566 | -7,901 | -3,586 | -3,132 | -4,296 |
Net Debt Issued (Repaid) | -3,852 | -4,403 | -281.82 | 5,939 | 1,378 |
Issuance of Common Stock | 61.02 | 13.74 | 13.67 | 36.18 | 34.99 |
Common Dividends Paid | -229.9 | -135.17 | - | -224.31 | -179.15 |
Other Financing Activities | -2,405 | -2,409 | -1,871 | -1,538 | -1,392 |
Financing Cash Flow | -6,426 | -6,933 | -2,139 | 4,213 | -157.96 |
Foreign Exchange Rate Adjustments | -5.38 | 1.62 | 1.46 | 1.28 | -12.2 |
Miscellaneous Cash Flow Adjustments | -0.22 | -1.35 | -3.39 | - | - |
Net Cash Flow | -484.56 | -1,425 | 1,328 | 448.96 | -564 |
Free Cash Flow | 4,419 | 5,829 | -505.27 | -4,012 | 1,840 |
Free Cash Flow Growth | -24.20% | - | - | - | 235.77% |
Free Cash Flow Margin | 9.68% | 14.98% | -1.37% | -13.07% | 5.55% |
Free Cash Flow Per Share | 48.02 | 64.06 | -5.61 | -44.70 | 20.50 |
Cash Interest Paid | 2,405 | 2,922 | 2,242 | 1,538 | 1,394 |
Cash Income Tax Paid | -670.39 | -242.47 | -876.45 | -23.28 | -1,568 |
Levered Free Cash Flow | 2,108 | 1,853 | 2,939 | -8,600 | -971.5 |
Unlevered Free Cash Flow | 3,404 | 3,343 | 4,299 | -7,689 | -194 |
Change in Working Capital | -1,637 | -787.32 | -4,578 | -1,899 | -3,281 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.